


TROGARZO® Enrollment Form

 **Trogarzo®**
(ibalizumab-uiyk)
Injection
200 mg/1.33 mL (150 mg/mL)

To enroll, fax all documents to 1-855-836-3069.

Please ensure all sections of Form are completed in full, with supporting documents included.

Questions? Contact a Patient Care Coordinator at 1-833-23-THERA (1-833-238-4372), Mon-Fri 8:30AM-8PM ET.

1. Patient Information

First Name _____ Middle Name _____ Date of Birth _____ Sex M F Gender Identity _____
Last Name _____ Preferred Language English Other _____
Address _____ Home phone _____ Mobile phone _____
City _____ State _____ Email _____
ZIP _____ SSN (last 4 digits) _____ Best time to contact AM PM Other _____
Are you pregnant or trying to become pregnant? Y N N/A

Alternate Contact/Caregiver _____ Telephone _____
Relationship to Patient _____ OK to leave message

2. Preferred Specialty Pharmacy:

Name of pharmacy _____ Telephone _____ Address _____
Contact _____ City _____ State _____

3. Prescriber Information

First Name _____ NPI # _____
Last Name _____ Tax ID # _____
Specialty _____ Medicaid # _____ State license # _____
Office/Clinic/Institution _____ Office Contact _____
Address _____ Office Telephone _____
City _____ Office Fax _____
State _____ ZIP _____ Office Email _____

4. Prescription

Rx: TROGARZO® (Ibalizumab-uiyk)
NDC: 62064-122-02
- 2 single-dose vials (200 mg/1.33 mL)

Prescription Type: New
 Continuing Therapy
 Restart

Loading Dose: (Please select one)

- Undiluted IV Push Loading:** 1 dose of 2,000 mg (10 vials) intravenous push over at least 90 seconds, with 2 to 5 mL post-intravenous push flush
- Diluted IV Infusion Loading:** 1 dose of 2,000 mg (10 vials) diluted in 250 mL of 0.9% NaCl, IV infusion over at least 30 minutes, with 30 mL post-infusion flush

Maintenance Dose: (Please select one)

- Undiluted IV Push Maintenance:** 800 mg (4 vials) intravenous push over at least 30 seconds, with 2 to 5 mL post-intravenous push flush every 2 weeks
Quantity: Dispense 1 month supply Refills _____
- Diluted IV Infusion Maintenance:** 800 mg (4 vials) diluted in 250 mL of 0.9% NaCl, IV infusion over at least 15 minutes, with 30 mL post-infusion flush, every 2 weeks
Quantity: Dispense 1 month supply Refills _____

Administration Orders per TROGARZO PI and Pharmacy Protocol:

- 0.9% NaCl 10 mL syringes, 0.9% NaCl 250 mL bags, 0.9% NaCl Flush 50 mL or 100 mL bags; Nursing Orders – Administer medication via skilled nursing, monitor patient status and response to therapy
- Authorization for Ancillary Supplies: Needles, syringes, etc., as needed for administration

Diagnosis (ICD-10): B20 (Human immunodeficiency virus (HIV)) Z16.33 (Resistance to antiviral drug (s))
 Other _____

5. Prescriber's Consent and Authorization

I certify that the patient and physician information contained in this enrollment form is complete and accurate to the best of my knowledge. I consent to be contacted for follow up information including if my patient is pregnant or trying to become pregnant. I have prescribed TROGARZO® based on my judgment of medical necessity and I will be supervising the patient's treatment. I have received the necessary authorization prior to the transmittal of health information to Theratechnologies Inc., and parties working with Theratechnologies Inc., to perform a preliminary assessment of insurance verification and determine patient eligibility for the THERA patient support® program. I authorize the forwarding of this prescription to a dispensing specialty pharmacy on behalf of myself and the patient. I understand that neither I nor the patient should seek reimbursement for any free product received under the program.

Special Note: The physician is to comply with their state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance of state-specific requirements could result in outreach to the prescriber.

Select one option:

Prescriber's Signature (no stamps; **Dispense As Written**) _____ Date: _____

OR

Prescriber's Signature (no stamps; **Substitution Permissible**) _____ Date: _____

6. Insurance Information

Patient does **not** have insurance

OR

Patient has insurance

Please complete the information below and include copies of **front** and **back** of insurance card(s)

Primary Medical Insurance _____ Policy # _____

Cardholder Name _____ Cardholder Date of Birth _____

Relationship to Cardholder _____ ID # _____

Secondary Medical Insurance _____ Policy # _____

Cardholder Name _____ Cardholder Date of Birth _____

Relationship to Cardholder _____ ID # _____

Prescription Drug Insurer/Pharmacy Benefit Manager (PBM)

Telephone _____ Policy # _____

Rx BIN # _____ Rx Group # _____ Rx PCN # _____

7. Site of Care

Initial Dose: (select one option)

Infusion Center _____

Infusion Center name _____

Address _____

Site contact name _____

Prescribing Physician Office _____

Home Infusion _____

All Subsequent Dosing: (select one option)

Same as Initial Dose _____

Different _____

Drug/Food Allergies _____

Medication History Included NKDA

Please attach complete antiretroviral list along with concomitant medication history

Patient Authorization and Signature

Patient Authorization to Use and Disclose Protected Health Information

I authorize health care providers and their staff involved in my care to disclose my Protected Health Information (as defined below), including but not limited to my medical record, pregnancy information and other health information on my completed Statement of Medical Necessity form or other forms, records that may contain information created by other persons, entities, physicians, and health care providers information concerning HIV/AIDS diagnosis and treatment, including HIV test results, as well as information regarding substance use disorder treatment services and mental health services (excluding psychotherapy notes) (collectively, "Protected Health Information"), to Theratechnologies Inc. and its agents, representatives, and direct and indirect service providers (collectively, "Theratechnologies"), so that Theratechnologies may:

1. Facilitate the filling of my prescription for and the delivery and administration of Theratechnologies products, including disclosing or redisclosing Protected Health Information to pharmacies;
2. Assist me in obtaining insurance coverage for Theratechnologies products, including disclosing or redisclosing Protected Health Information to health plans;
3. Partner me with a Nurse Navigator for training and adherence assistance. Interaction can be live audio/video training offering education for proper use, if applicable, administration and continuous adherence guidance. I have the right not to be recorded at any time. Theratechnologies will have access to my communications to provide adequate patient care. Any dissemination, storage or retention of an identifiable patient image or other information shall comply with federal and state laws and regulations requiring confidentiality;
4. Create deidentified and aggregate information to be used and shared for reimbursement, publication, or commercial purposes.

I authorize Theratechnologies to contact me by mail, email, video and/or telephone to enroll me in, and administer programs that provide support services.

To accomplish these purposes, I further authorize Theratechnologies to share information, including HIV/AIDS information, between and among the entities defined in this

Authorization as Theratechnologies. I understand that once my Protected Health Information is disclosed pursuant to this authorization, it may no longer be protected by federal privacy law and regulations known as "HIPAA" or state privacy laws and may be the subject to further disclosure by Theratechnologies and third parties with whom Theratechnologies may share the information. However, other state and federal laws may prohibit the recipient from disclosing specially protected information such as certain HIV/AIDS-related information, substance use disorder treatment information, and mental health information. I understand that I may refuse to sign this authorization. My refusal will not affect my ability to receive Theratechnologies products, treatment, payment, enrollment in a health plan, or eligibility for benefits but my refusal may limit my ability to receive certain support services that are provided by Theratechnologies.

I understand that health care providers may receive compensation, remuneration, or other value as a result of their use and disclosure of my Protected Health Information as described in this authorization.

I understand that this authorization will remain in effect for 10 years from the date of my signature, unless limited by state laws and regulations and/or I revoke it in writing by contacting Theratechnologies c/o

ASPN Pharmacies, LLC
290 West Mount Pleasant Ave
Building 2, 4th Floor, Suite 4210
Livingston, NJ 07039 United States

If I revoke this authorization, Theratechnologies and any third parties that are notified of my revocation will stop using my Protected Health Information for the purposes outlined in this authorization, but the revocation will not affect prior use or disclosure of my Protected Health Information in reliance on this authorization. I have the right to receive a copy of this authorization after I sign it.

I understand that the support services provided by Theratechnologies that are described in this authorization can be changed at any time, without prior notification.

By checking this box, I authorize Theratechnologies to:

- Send me text messages about my TROGARZO®. I understand that standard data fees and text messaging fees may apply based on my mobile plan; and
 - Provide me with free educational information, information about clinical trials, and marketing materials; and
 - Conduct surveys to measure my satisfaction with Theratechnologies products and services.
- Conduct regular follow-ups with me (if I am pregnant or of childbearing potential) to monitor pregnancy exposure while being on Trogarzo treatment.

Patient Name _____ Date of Birth _____

Address _____ Telephone _____

Patient's Signature _____ Date _____

If you are the patient's representative, identify your relationship to the patient and state basis of authority

NOTICE TO RECIPIENT OF INFORMATION:

HIV-related Information: To the extent that HIV-related information has been provided to you, such information has been disclosed to you from records whose confidentiality may be protected by federal and state law. Such laws may prohibit you from making any further disclosure of the HIV-related information without the specific written consent of the person to whom it pertains, or as otherwise permitted by said laws. When obtaining such written consent, you must expressly identify that "HIV-related information is being disclosed" (a general authorization for the release of the entire medical file, for example, is NOT sufficient for this purpose). An oral disclosure shall be accompanied or followed by such notice within 10 days.